Data / Form D filings / Zero Point Five Therapeutics, Inc.
Zero Point Five Therapeutics, Inc.: Form D filings
Zero Point Five Therapeutics, Inc., a biotechnology company in Baltimore, MD, filed 2 Form D notices with the SEC between 2023 and 2025. The latest, on April 17, 2025, reports $4.3 million sold of a $5.3 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 915 S. EATON STREET, Baltimore, MD, 21224
- Phone
- (301) 327-0118
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- District Of Columbia
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1985295
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 17, 2025 | New notice | $5,333,250 | $4,299,420 | $1,033,830 | 10 | Apr 2, 2025 | sec.gov |
| Jul 12, 2023 | New notice | $10,140,859 | $7,220,517 | $2,920,342 | 15 | Jun 27, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ben Auspitz | Director | |
| Joseph Amprey III | Executive Officer, Director | |
| Jodi Jahic | Director |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Apr 14, 2025 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Zero Point Five Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.